US FDA approves Mirum's drug for rare bone disorder
25/09/2026 19:57
US FDA approves Mirum's drug for rare bone disorder Sept 25 (Reuters) - The US Food and Drug Administration has approved Mirum Pharmaceuticals' MIRM.O drug to treat a rare bone disorder, the regulator said on Friday.
(Reporting by Kunal Das and Christy Santhosh in Bengaluru; Editing by Jonathan Ananda)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement